Chaonan Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chaonan Sun has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Cheng Cheng
Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, China
2 shared publicationsCong Shang
Department of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, China
1 shared publicationDandan Xu
State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
1 shared publication- Fei Xue
State Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
1 shared publication - Jing Zhang
Department of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, China
1 shared publication Jinling Hu
Department of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, China
1 shared publication
Latest Publications
- Open Access
- 25 October 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-19
Insulin resistance-related indices, genetic risk, and the risk of cardiovascular disease in individuals with preclinical or clinical obesity: a large prospective cohort study in the UK biobank
Insulin resistance (IR)-related indices are validated prognostic markers in metabolic disorders, but have not been applied to preclinical or clinical obesity. This study aimed to investigate the relationship between IR-related indices and cardiovascular disease (CVD) incidence, considering genetic factors and biomarkers. This prospective study analyzed 112,866 UK Biobank participants with preclinical or clinical obesity. IR-related indices were evaluated: triglyceride-glucose (TyG) index, TyG-body mass index (TyG-BMI), TyG-waist circumference (TyG-WC), and TyG-waist-to-height ratio (TyG-WHtR). Genetic risk was estimated using the polygenic risk score. Outcomes, including total CVD, coronary artery disease (CAD), and stroke, were ascertained through medical records linkage. Cox proportional hazard models were used to evaluate the associations and modification effects of genetic risk. Incremental predictive value was assessed by net reclassification index (NRI) and integrated discrimination improvement index (IDI). Mediation analyses explored the role of inflammatory, hepatic, and renal biomarkers. Over a median follow-up period of 13.45 years, 21,601 total CVD, 11,942 CAD, and 3347 stroke cases were documented. Compared with the lowest quartile of IR-related indices, participants in the highest quartile presented increased CVD risk. For total CVD, hazard ratios (HRs) (95% confidence intervals, CIs) for the fourth versus the first quartiles were 1.33 (1.28–1.39) for TyG-BMI, 1.41 (1.34–1.48) for TyG-WC, and 1.25 (1.20–1.31) for TyG-WHtR. All IR-related indices demonstrated significant associations with CAD. Borderline significant associations were observed for stroke. Distinct dose-response association patterns with total CVD were observed: TyG-BMI and TyG-WHtR exhibited nonlinear relationships, while TyG-WC demonstrated a linear association. The CVD risk was highest in individuals with high genetic risk and high IR indices, with an additive interaction between TyG-WC and genetic risk being observed. Significantly higher NRI and IDI were observed for TyG-WC, TyG-BMI, and TyG-WHtR in predicting CVD, with TyG-WC achieving the highest performance. Mediation analyses indicated that inflammation, liver, and renal biomarkers might partially mediate the relationship. Elevated IR-related indices, particularly TyG-WC, were associated with increased total CVD and CAD risks in preclinical or clinical obesity. Additive effects of TyG-WC and genetic risk on CVD were revealed, with mediating biomarkers suggesting potential targeted interventions for CVD risk reduction.
- 25 October 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-19
Open AccessInsulin resistance-related indices, genetic risk, and the risk of cardiovascular disease in individuals with preclinical or clinical obesity: a large prospective cohort study in the UK biobank
Insulin resistance (IR)-related indices are validated prognostic markers in metabolic disorders, but have not been applied to preclinical or clinical obesity. This study aimed to investigate the relationship between IR-related indices and cardiovascular disease (CVD) incidence, considering genetic factors and biomarkers. This prospective study analyzed 112,866 UK Biobank participants with preclinical or clinical obesity. IR-related indices were evaluated: triglyceride-glucose (TyG) index, TyG-body mass index (TyG-BMI), TyG-waist circumference (TyG-WC), and TyG-waist-to-height ratio (TyG-WHtR). Genetic risk was estimated using the polygenic risk score. Outcomes, including total CVD, coronary artery disease (CAD), and stroke, were ascertained through medical records linkage. Cox proportional hazard models were used to evaluate the associations and modification effects of genetic risk. Incremental predictive value was assessed by net reclassification index (NRI) and integrated discrimination improvement index (IDI). Mediation analyses explored the role of inflammatory, hepatic, and renal biomarkers. Over a median follow-up period of 13.45 years, 21,601 total CVD, 11,942 CAD, and 3347 stroke cases were documented. Compared with the lowest quartile of IR-related indices, participants in the highest quartile presented increased CVD risk. For total CVD, hazard ratios (HRs) (95% confidence intervals, CIs) for the fourth versus the first quartiles were 1.33 (1.28–1.39) for TyG-BMI, 1.41 (1.34–1.48) for TyG-WC, and 1.25 (1.20–1.31) for TyG-WHtR. All IR-related indices demonstrated significant associations with CAD. Borderline significant associations were observed for stroke. Distinct dose-response association patterns with total CVD were observed: TyG-BMI and TyG-WHtR exhibited nonlinear relationships, while TyG-WC demonstrated a linear association. The CVD risk was highest in individuals with high genetic risk and high IR indices, with an additive interaction between TyG-WC and genetic risk being observed. Significantly higher NRI and IDI were observed for TyG-WC, TyG-BMI, and TyG-WHtR in predicting CVD, with TyG-WC achieving the highest performance. Mediation analyses indicated that inflammation, liver, and renal biomarkers might partially mediate the relationship. Elevated IR-related indices, particularly TyG-WC, were associated with increased total CVD and CAD risks in preclinical or clinical obesity. Additive effects of TyG-WC and genetic risk on CVD were revealed, with mediating biomarkers suggesting potential targeted interventions for CVD risk reduction.
- Top Cited PapersOpen Access
- 2 May 2025
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 44 (1) , 1-32
Harnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy
Extracellular vesicles (EVs), particularly engineered variants, have emerged as promising tools in cancer immunotherapy due to their inherent ability to modulate immune responses and deliver therapeutic agents with high specificity and minimal toxicity. These nanometer-sized vesicles, which include exosomes (Exos) and other subtypes, naturally participate in intercellular communication and are capable of carrying a diverse range of bioactive molecules, including proteins, lipids, RNAs, and metabolites. Recent advancements in the biogenesis of engineered EVs, such as strategies to modify their surface characteristics and cargo, have significantly expanded their potential as effective vehicles for targeted cancer therapies. Tailoring the contents of EVs, such as incorporating immunomodulatory molecules or gene-editing tools (GETs), has shown promising outcomes in enhancing anti-tumor immunity and overcoming the immunosuppressive tumor microenvironment (TME). Moreover, optimizing delivery mechanisms, through both passive and active targeting strategies, is crucial for improving the clinical efficacy of EV-based therapies. This review provides an overview of recent developments in the engineering of EVs for cancer immunotherapy, focusing on their biogenesis, methods of content customization, and innovations in cargo delivery. Additionally, the review addresses the challenges associated with the clinical translation of EV-based therapies, such as issues related to scalability, safety, and targeted delivery. By offering insights into the current state of the field and identifying key areas for future research, this review aims to advance the application of engineered EVs in cancer treatment.
- 2 May 2025
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 44 (1) , 1-32
Top Cited PapersOpen AccessHarnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy
Extracellular vesicles (EVs), particularly engineered variants, have emerged as promising tools in cancer immunotherapy due to their inherent ability to modulate immune responses and deliver therapeutic agents with high specificity and minimal toxicity. These nanometer-sized vesicles, which include exosomes (Exos) and other subtypes, naturally participate in intercellular communication and are capable of carrying a diverse range of bioactive molecules, including proteins, lipids, RNAs, and metabolites. Recent advancements in the biogenesis of engineered EVs, such as strategies to modify their surface characteristics and cargo, have significantly expanded their potential as effective vehicles for targeted cancer therapies. Tailoring the contents of EVs, such as incorporating immunomodulatory molecules or gene-editing tools (GETs), has shown promising outcomes in enhancing anti-tumor immunity and overcoming the immunosuppressive tumor microenvironment (TME). Moreover, optimizing delivery mechanisms, through both passive and active targeting strategies, is crucial for improving the clinical efficacy of EV-based therapies. This review provides an overview of recent developments in the engineering of EVs for cancer immunotherapy, focusing on their biogenesis, methods of content customization, and innovations in cargo delivery. Additionally, the review addresses the challenges associated with the clinical translation of EV-based therapies, such as issues related to scalability, safety, and targeted delivery. By offering insights into the current state of the field and identifying key areas for future research, this review aims to advance the application of engineered EVs in cancer treatment.
- Top Cited PapersOpen Access
- 31 May 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1409653
Triglyceride-rich lipoproteins and cardiovascular diseases
The global prevalence of cardiovascular diseases (CVD) continues to rise steadily, making it a leading cause of mortality worldwide. Atherosclerosis (AS) serves as a primary driver of these conditions, commencing silently at an early age and culminating in adverse cardiovascular events that severely impact patients’ quality of life or lead to fatality. Dyslipidemia, particularly elevated levels of low-density lipoprotein cholesterol (LDL-C), plays a pivotal role in AS pathogenesis as an independent risk factor. Research indicates that abnormal LDL-C accumulation within arterial walls acts as a crucial trigger for atherosclerotic plaque formation. As the disease progresses, plaque accumulation may rupture or dislodge, resulting in thrombus formation and complete blood supply obstruction, ultimately causing myocardial infarction, cerebral infarction, and other common adverse cardiovascular events. Despite adequate pharmacologic therapy targeting LDL-C reduction, patients with cardiometabolic abnormalities remain at high risk for disease recurrence, highlighting the importance of addressing lipid risk factors beyond LDL-C. Recent attention has focused on the causal relationship between triglycerides, triglyceride-rich lipoproteins (TRLs), and their remnants in AS risk. Genetic, epidemiologic, and clinical studies suggest a causal relationship between TRLs and their remnants and the increased risk of AS, and this dyslipidemia may be an independent risk factor for adverse cardiovascular events. Particularly in patients with obesity, metabolic syndrome, diabetes, and chronic kidney disease, disordered TRLs and its remnants levels significantly increase the risk of atherosclerosis and cardiovascular disease development. Accumulation of over-synthesized TRLs in plasma, impaired function of enzymes involved in TRLs lipolysis, and impaired hepatic clearance of cholesterol-rich TRLs remnants can lead to arterial deposition of TRLs and its remnants, promoting foam cell formation and arterial wall inflammation. Therefore, understanding the pathogenesis of TRLs-induced AS and targeting it therapeutically could slow or impede AS progression, thereby reducing cardiovascular disease morbidity and mortality, particularly coronary atherosclerotic heart disease.
- 31 May 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1409653
Top Cited PapersOpen AccessTriglyceride-rich lipoproteins and cardiovascular diseases
The global prevalence of cardiovascular diseases (CVD) continues to rise steadily, making it a leading cause of mortality worldwide. Atherosclerosis (AS) serves as a primary driver of these conditions, commencing silently at an early age and culminating in adverse cardiovascular events that severely impact patients’ quality of life or lead to fatality. Dyslipidemia, particularly elevated levels of low-density lipoprotein cholesterol (LDL-C), plays a pivotal role in AS pathogenesis as an independent risk factor. Research indicates that abnormal LDL-C accumulation within arterial walls acts as a crucial trigger for atherosclerotic plaque formation. As the disease progresses, plaque accumulation may rupture or dislodge, resulting in thrombus formation and complete blood supply obstruction, ultimately causing myocardial infarction, cerebral infarction, and other common adverse cardiovascular events. Despite adequate pharmacologic therapy targeting LDL-C reduction, patients with cardiometabolic abnormalities remain at high risk for disease recurrence, highlighting the importance of addressing lipid risk factors beyond LDL-C. Recent attention has focused on the causal relationship between triglycerides, triglyceride-rich lipoproteins (TRLs), and their remnants in AS risk. Genetic, epidemiologic, and clinical studies suggest a causal relationship between TRLs and their remnants and the increased risk of AS, and this dyslipidemia may be an independent risk factor for adverse cardiovascular events. Particularly in patients with obesity, metabolic syndrome, diabetes, and chronic kidney disease, disordered TRLs and its remnants levels significantly increase the risk of atherosclerosis and cardiovascular disease development. Accumulation of over-synthesized TRLs in plasma, impaired function of enzymes involved in TRLs lipolysis, and impaired hepatic clearance of cholesterol-rich TRLs remnants can lead to arterial deposition of TRLs and its remnants, promoting foam cell formation and arterial wall inflammation. Therefore, understanding the pathogenesis of TRLs-induced AS and targeting it therapeutically could slow or impede AS progression, thereby reducing cardiovascular disease morbidity and mortality, particularly coronary atherosclerotic heart disease.